Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

learn more about Select Allied Health NASH Professionals Cirrhosis Clinical Trials NASH Companies COVID-19 Diabetes Diagnostics Histopathology NAIL-NITs Doctors Drugs/Drug Classes Epidemiology Fatty Liver FDA Investors Liver Science Major NASH Meetings Metabolic Diseases NAFLD NASH NASH-TAG Obesity Patients Pediatric NASH Prevalence/Incidence Public Health Special Subpopulations Suggested Reading

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?

Would you like to participate ask a question join the surfers in our next episode?

S3-E24.2 – Controversy at the Innovations in NAFLD Care Conference: What is Patient Empowerment In This Situation?

Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway. This conversation centers around areas for controversy, including data-driven patient empowerment and what the proper name for this disease should be.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.